A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-01-12

Study Completion Date

2017-05-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this two-part study is to measure how much of the study drug gets into the blood stream and how long it takes the body to get rid of it. In Part A, each participant will receive two treatments, a single dose and a single dose with continuous infusion of U-500R insulin, both administered just under the skin. Participants who complete Part A will continue into Part B where they will be assigned to 1 of 2 treatments with U-500R insulin, injected either twice or three times daily under the skin for 5-10 days. This study can last from 7-14 weeks including initial screening and follow up.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

NCT02561078

Type 2 Diabetes Mellitus

COMPLETED PHASE3

Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes

NCT01774968

Diabetes Mellitus, Type 2

COMPLETED PHASE4

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

NCT00606034

Type 2 Diabetes Insulin Resistance

COMPLETED PHASE4

A Study of LY3209590 in Participants With Type 2 Diabetes

NCT03367377

Diabetes Mellitus, Type 2

COMPLETED PHASE1

A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy

NCT02623465

Diabetes Mellitus, Type 2

WITHDRAWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A: U-500R Single Injection

Bolus of U-500R administered via single subcutaneous (SC) injection.

Group Type EXPERIMENTAL

U-500R

Intervention Type DRUG

Part A: U-500R CSII

Bolus of U-500R administered via continuous subcutaneous insulin infusion (CSII).

Group Type EXPERIMENTAL

U-500R

Intervention Type DRUG

Part B: U-500R TID

U-500R administered thrice-daily (TID) via SC injection under steady state conditions for 5 to 10 days

Group Type EXPERIMENTAL

U-500R

Intervention Type DRUG

Part B: U-500R BID

U-500R administered twice-daily (BID) via SC injection under steady state conditions for 5 to 10 days

Group Type EXPERIMENTAL

U-500R

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

U-500R

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Humulin R U-500 LY041001 Humulin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females with type 2 diabetes mellitus (T2DM)
* Are current users of U-100, U-200 and/or U-300 insulin/analog as, basal, premixed and/or basal/bolus delivered with any injection device (pens and/or syringe/vial but excluding continuous subcutaneous infusion (CSII)/insulin pump use in the preceding 3 months), taking a total daily dose (TDD) of greater than or equal to (≥) 150 units (U) or at least one dose greater than (\>) 100 U as part of a multiple daily injection (MDI) regimen and TDD less than or equal to (≤)3.0 units per kilogram (U/kg)
* Concomitant antihyperglycemic agent(s) (AHA) therapy may include: metformin (MET), dipeptidyl peptidase 4 inhibitors, pioglitazone (doses ≤30 milligrams per day (mg/day)), glucagon like peptide (GLP)-1 receptor agonists, sodium-glucose co-transporter-2 (SGLT2) inhibitors, except in combination with GLP-1 receptor agonists
* Participant's antihyperglycemic agent (AHA) therapy must have been stable for ≥3 months (except for weekly GLP-1 receptor agonists which must have been stable for ≥4 months)
* Have hemoglobin A1c (HbA1c) 7.5-11.5 percent (%)

Exclusion Criteria

* Have type 1 diabetes mellitus (T1DM), or other types of diabetes mellitus apart from T2DM
* Have known hypersensitivities or allergies to insulin, excipients contained in insulin products, or related compounds
* Have used U-500R within 3 months prior to screening
* Have used rosiglitazone, pramlintide, once weekly or twice daily exenatide, or other injectable or oral antihyperglycemic agent(s) not listed in the inclusion criterion; or are taking oral antidiabetic medications at doses exceeding the respective product labels
* Have had a blood transfusion or severe blood loss within 3 months prior to screening or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia which may affect reliability of HbA1c measurements

Minimum Eligible Age

18 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No